Literature DB >> 19411119

Inflammation in right ventricular dysfunction due to thromboembolic pulmonary hypertension.

Stephan von Haehling1, Ralph S von Bardeleben, Thorsten Kramm, Yardena Thiermann, Margit Niethammer, Wolfram Doehner, Stefan D Anker, Thomas Munzel, Eckhard Mayer, Sabine Genth-Zotz.   

Abstract

OBJECTIVES AND
BACKGROUND: Activation of the immune system is well established in patients with chronic heart failure (CHF) and impaired left ventricular function. High levels of pro-inflammatory cytokines are associated with a poor prognosis. Chronic thromboembolic pulmonary hypertension (CTEPH) frequently leads to impaired right ventricular function. It is not known whether such patients display chronic immune activation as well. METHODS AND
RESULTS: We studied 49 patients with CTEPH (50±2 years, right ventricular ejection fraction [RVEF] 29±2%, left ventricular ejection fraction [LVEF] 51±3%, mean±SEM) and compared their results with 17 patients with CHF (71±2 years, LVEF 23±1%) and 34 age-matched control subjects (age 57±2 years). We studied serum levels of tumor necrosis factor-α (TNFα), its soluble receptors 1 and 2 (sTNFR1 and 2), interleukin-10 (IL-10) and plasma N-terminal-pro-B-type natriuretic peptide (NT-proBNP). Serum TNFα was not different in CTEPH compared with CHF patients (p=0.67) but both their levels were significantly higher than in controls (both p<0.001). Similar results were obtained for sTNFR1, sTNFR2, and IL-10. Levels of NT-proBNP were not different in patients with CTEPH or CHF (p=0.54), but significantly higher than in control subjects (both p<0.001). There were significant correlations between RVEF as assessed by magnetic resonance imaging and sTNFR1, sTNFR2, IL-6, high sensitivity C-reactive protein, and NT-proBNP (all p<0.05) in patients with CTEPH.
CONCLUSION: Similar levels of immune activation as reflected by high levels of pro-inflammatory cytokines are present in patients with isolated right ventricular dysfunction due to CTEPH and patients with CHF and left ventricular dysfunction.
Copyright © 2009 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 19411119     DOI: 10.1016/j.ijcard.2009.04.019

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  13 in total

Review 1.  Iron deficiency and cardiovascular disease.

Authors:  Stephan von Haehling; Ewa A Jankowska; Dirk J van Veldhuisen; Piotr Ponikowski; Stefan D Anker
Journal:  Nat Rev Cardiol       Date:  2015-07-21       Impact factor: 32.419

2.  Proteomic and Metabolomic Analyses of Right Ventricular Failure due to Pulmonary Arterial Hypertension.

Authors:  Xiaohan Qin; Chuxiang Lei; Li Yan; Haidan Sun; Xiaoyan Liu; Zhengguang Guo; Wei Sun; Xiaoxiao Guo; Quan Fang
Journal:  Front Mol Biosci       Date:  2022-07-05

3.  Native T1 and T2 mapping by cardiovascular magnetic resonance imaging in pressure overloaded left and right heart diseases.

Authors:  Jing Wang; Hang Zhao; Yue Wang; Howard C Herrmann; Walter R T Witschey; Yuchi Han
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

4.  (18)FDG PET imaging can quantify increased cellular metabolism in pulmonary arterial hypertension: A proof-of-principle study.

Authors:  Guy Hagan; Mark Southwood; Carmen Treacy; Robert Mackenzie Ross; Elaine Soon; James Coulson; Karen Sheares; Nicholas Screaton; Joanna Pepke-Zaba; Nicholas W Morrell; James H F Rudd
Journal:  Pulm Circ       Date:  2011 Oct-Dec       Impact factor: 3.017

5.  Comparison of gene expression profiles and related pathways in chronic thromboembolic pulmonary hypertension.

Authors:  Song Gu; Pixiong Su; Jun Yan; Xitao Zhang; Xiangguang An; Jie Gao; Rui Xin; Yan Liu
Journal:  Int J Mol Med       Date:  2013-12-10       Impact factor: 4.101

6.  Local and systemic RAGE axis changes in pulmonary hypertension: CTEPH and iPAH.

Authors:  Bernhard Moser; Anna Megerle; Christine Bekos; Stefan Janik; Tamás Szerafin; Peter Birner; Ana-Iris Schiefer; Michael Mildner; Irene Lang; Nika Skoro-Sajer; Roela Sadushi-Kolici; Shahrokh Taghavi; Walter Klepetko; Hendrik Jan Ankersmit
Journal:  PLoS One       Date:  2014-09-04       Impact factor: 3.240

7.  Relationship Between Prohormone Brain Natriuretic Peptide (NT-proBNP) Level and Severity of Pulmonary Dysfunction in Patients With Chronic Congestive Heart Failure.

Authors:  Masoud Nazemiyeh; Akbar Sharifi; Farhad Amiran; Leili Pourafkari; Mohammadreza Taban Sadeghi; Hossein Namdar; Mohsen Abbasnezhad
Journal:  J Cardiovasc Thorac Res       Date:  2015-03-29

Review 8.  Inflammatory Mediators Drive Adverse Right Ventricular Remodeling and Dysfunction and Serve as Potential Biomarkers.

Authors:  Akylbek Sydykov; Argen Mamazhakypov; Aleksandar Petrovic; Djuro Kosanovic; Akpay S Sarybaev; Norbert Weissmann; Hossein A Ghofrani; Ralph T Schermuly
Journal:  Front Physiol       Date:  2018-05-23       Impact factor: 4.566

9.  The Clinical Significance of HbA1c in Operable Chronic Thromboembolic Pulmonary Hypertension.

Authors:  Manuel Jonas Richter; Katrin Milger; Sarah Haase; Natascha Sommer; Khodr Tello; Werner Seeger; Eckhard Mayer; Christoph Benjamin Wiedenroth; Friedrich Grimminger; Wolfgang George; Hossein Ardeschir Ghofrani; Stefan Guth; Henning Gall
Journal:  PLoS One       Date:  2016-03-31       Impact factor: 3.240

10.  Inflammatory cytokines and plasma redox status responses in hypertensive subjects after heat exposure.

Authors:  S F Fonseca; V A Mendonça; M C Teles; V G C Ribeiro; R Tossige-Gomes; C D C Neves; E Rocha-Vieira; L H R Leite; D D Soares; C C Coimbra; A C R Lacerda
Journal:  Braz J Med Biol Res       Date:  2016-02-02       Impact factor: 2.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.